Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascentage Pharma Group International (NASDAQ: AAPG) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. Ascentage Pharma files annual reports on Form 20‑F and current reports on Form 6‑K under the Securities Exchange Act of 1934, reflecting its status as a NASDAQ‑listed biopharmaceutical company with operations in oncology and hematology.
Recent Form 6‑K filings have furnished press releases on a range of material topics, including pivotal Phase II and Phase III clinical data for Lisaftoclax and olverembatinib, regulatory clearances from the U.S. FDA and EMA for global registrational studies such as POLARIS‑1 and GLORA, publication of olverembatinib data in gastrointestinal stromal tumors, investor conference participation, interim financial results and business updates, and corporate governance items such as indemnification agreements and interest payments related to top‑up placements. These filings help investors understand the progress of Ascentage Pharma’s apoptotic pathway inhibitors, BCR‑ABL1 inhibitor programs, and protein degrader pipeline.
On Stock Titan, each new AAPG filing is captured from EDGAR and presented with AI‑generated highlights to explain the context and key points in clear language. Users can review Form 6‑K submissions related to clinical milestones, financing activities, and board decisions, and can connect these disclosures to the company’s broader oncology strategy. While Ascentage Pharma’s core SEC reporting currently emphasizes 6‑K updates, investors can also reference its Form 20‑F annual report for a more detailed discussion of risk factors, business overview, and financial statements.
In addition, this page offers quick access to historical filings so that readers can trace how Ascentage Pharma’s hematology and solid tumor programs, global partnerships, and capital markets activities have evolved over time. AI‑assisted summaries help reduce the time needed to interpret lengthy documents, highlighting items such as major clinical trial announcements, regulatory interactions, and key corporate actions disclosed in AAPG’s SEC submissions.
Ascentage Pharma Group International (AAPG) filed a Form 6-K that furnishes a press release titled “Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025.” The release is included as Exhibit 99.1. The filing notes the company’s plan to engage investors at two conferences in November 2025 and provides the press release for additional details.
Ascentage Pharma Group International filed a Form 6-K noting that it issued a press release on October 7, 2025. The press release, furnished as Exhibit 99.1, announces that the company will participate in three investor conferences in October 2025. These conferences are opportunities for the company to present its business and engage with the investment community, but no financial results, transactions, or other material changes are detailed in this report.
Ascentage Pharma Group International filed a Form S-8 to register the issuance of an additional 5,800,000 ordinary shares of common stock, par value US$0.0001 per share, under its Amended 2022 Restricted Share Unit Scheme. This expands the pool of shares available for equity awards to employees and other eligible participants.
The company had previously registered 5,272,695 ordinary shares for the original 2022 Restricted Share Unit Scheme on a prior Form S-8. The new filing incorporates that earlier registration by reference and includes customary exhibits such as legal opinions, auditor consents and the amended RSU scheme document. The registration statement is signed on behalf of the company by its Chief Executive Officer, Dajun Yang.
Ascentage Pharma Group International filed a Post-Effective Amendment No. 1 to its Form S-8 to adjust how previously registered equity is allocated between employee incentive plans. The company is reallocating 5,800,000 Ordinary Shares from its Post-IPO Option Scheme, as amended, to its 2022 Restricted Share Unit Scheme, as amended. This amendment deregisters the Ordinary Shares that were registered under the earlier Form S-8 for use in the Post-IPO Option Scheme but will not be used for awards under that option plan. At the same time, the company is filing a new Form S-8 to register Ordinary Shares now available for offer or sale under the 2022 RSU Scheme.
Ascentage Pharma Group International furnished a Form 6-K highlighting its 2025 interim results disclosures and governance updates. The company attached a press release on unaudited six‑month financial results and a Hong Kong Stock Exchange announcement as exhibits.
The filing also explains a previously closed offshore placement and top‑up subscription in which an affiliate of the CEO sold 22 million ordinary shares and received 22 million new ordinary shares at HKD68.60 per share, providing the company with approximately HKD1,492 million (about US$190.1 million) in net proceeds. In connection with this and a prior top‑up placement, the board approved a new form of indemnification agreement extending protections to certain affiliates of directors and officers and authorized payment of up to US$600,000 in interest to those indemnified persons whose share loans facilitated the placements.
Ascentage Pharma Group International submitted a Form 6-K noting that it has furnished two communications about a key clinical milestone for its oncology candidate lisaftoclax. On August 17, 2025, the company issued a press release announcing that a global registrational Phase III trial of lisaftoclax for the first-line treatment of patients with myelodysplastic syndrome was cleared by the US FDA and the European Medicines Agency (EMA). On August 18, 2025, it also published a voluntary announcement on the Hong Kong Stock Exchange describing a global registrational Phase III study of lisaftoclax for first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS) cleared by the FDA and EMA.
Ascentage Pharma Group International submitted a Form 6-K noting that it has furnished a Hong Kong Stock Exchange announcement titled “Notice of Board Meeting.” The announcement, dated August 8, 2025, is attached as Exhibit 99.1. The report is signed by Chief Executive Officer Dajun Yang.